Better news for tolvaptan as Japan clears use in cirrhosis
This article was originally published in Scrip
Executive Summary
Otsuka Pharmaceutical has had better news for its aquaretic agent tolvaptan, receiving an approval for a new indication in Japan following a rejection from the US FDA in a different setting last month.